Objective. Fetal exposure to maternal anti-SSA/ Ro antibodies is necessary but not sufficient for the development of autoimmune congenital heart block (CHB), suggesting that other factors, such as fetal genetic predisposition, are important. Given the previously described association between major histocompatibility complex alleles and CHB risk, we undertook the present study to test the hypothesis that a variant form of HLA-C Asn80Lys, which binds with high affinity to an inhibitory killer cell immunoglobulin-like receptor (KIR) and thus renders natural killer (NK) cells incapable of restricting inflammation, contributes to the development of CHB.
were genotyped on the Immunochip single-nucleotide polymorphism microarray. Imputation was used to identify associations at HLA-C Asn80Lys (Asn, C1; Lys, C2) and KIR. Tests for association were performed using logistic regression. McNemar's test and the pedigree disequilibrium test (PDT) were used for matched analyses between affected and unaffected children.
Results. Compared with out-of-study controls of the same sex, the C2 allele was less frequent in the mothers (odds ratio [OR] 0.63, P = 0.0014) and more frequent in the fathers (OR 1.40, P = 0.0123), yielding a significant sex-by-C2 interaction (P = 0.0002). The C2 allele was more frequent in affected siblings than in unaffected siblings (OR 3.67, P = 0.0025), which was consistent with the PDT results (P = 0.016); these results were observed in both sexes and across the US and European cohorts. There was no difference in the frequency of the inhibitory KIR genotype (KIR AA) between affected and unaffected children (P = 0.55).
Conclusion. These data establish C2 as a novel genetic risk factor associated with CHB. This observation supports a model in which fetuses with C2 ligand expression and maternal anti-SSA/Ro positivity may have impaired NK cell surveillance, resulting in unchecked cardiac inflammation and scarring.
Congenital heart block (CHB) is an autoimmune disease (1) characterized by the presence of maternal antibodies directed against components of the SSA/Ro-SSB/La ribonucleoprotein complex. Injury to the fetal heart most often occurs during gestational weeks 18-24 and is presumed to be dependent upon the transport of maternal IgG autoantibodies by neonatal Fc receptor. Maternal health status accompanying the production of anti-Ro/La autoantibodies is not a risk factor for this fetal disease. Many of the mothers are clinically asymptomatic at the time of CHB detection, and thus maternal autoantibody status is tested only after fetal injury is identified (1) . Advanced conduction abnormalities are the signature phenotype of anti-SSA/Ro-associated cardiac injury. However, the disease spectrum can also extend to the myocardium and endocardium. Third-degree block is not reversible and is associated with significant mortality (17.5%) and morbidity (placement of a pacemaker is required in 70% of cases) (2) . The case fatality rate approaches 50% when extranodal disease is present (2) . Maternal anti-SSA/Ro antibodies are identified in >85% of cases of CHB; however, their presence alone is not sufficient for CHB development. Only an estimated 2% of anti-SSA/Ro-positive mothers will have a CHB-affected child, and furthermore, the recurrence rate is well below 100%, i.e.,~18%. Thus, although fetal exposure to maternal anti-Ro/SSA antibodies is necessary, it is not the sole driver of CHB progression. Identification of a potential fetal genetic contribution is challenging to distinguish from the maternal genome since there are strong associations between anti-SSA/Ro positivity and the extended HLA-DRB1*0301 and HLA-A1/B8 haplotypes (3). Not surprisingly, the first reported large-scale genomewide association study, with 116 CHB cases versus healthy controls (4), demonstrated an association of 17 single-nucleotide polymorphisms (SNPs) at 6p21 within the HLA region. In addition to reflecting the presumed contribution to the generation of maternal autoantibodies, this association is of interest given an interacting genetic effect between 6p21 and 19q13 (5). Specifically, HLA-C (6p21) acts as a ligand for the checkpoint receptor killer cell immunoglobulin-like receptor (KIR) encoded within 19q13 (5) . A dimorphism at position 80 in HLA-C proteins creates 2 epitope subgroups, defined by their KIR interactions: C1 (Asn80) and C2 (Lys80) (5) . The C1 designation includes HLA-C alleles *01, *03, *07, *08, *12, *13, *14, *16:01, and *16:04, and C2 includes *02, *04, *05, *06, *15, *17, *18, and *16:02.
To date, there has been no published study of the interacting effect of KIR and HLA-C in anti-SSA/ Ro-exposed CHB-affected and unaffected siblings. To test the a priori hypothesis that a fetal genetic contribution to the pathogenesis of CHB might involve inhibition of checkpoint inhibitors, we undertook the current study focusing on the HLA-C Asn80Lys and KIR genes. Using US-and Europe-based cohorts, we specifically addressed whether the C1/C2 dimorphism constitutes a susceptibility locus for the development of CHB.
PATIENTS AND METHODS
Patients and samples. Family data were collected from several sources: primarily, the US Research Registry for Neonatal Lupus (RRNL) (138 CHB cases), with additional samples from collaborations in Italy (28 CHB cases) and France (28 CHB cases). There were 4 cases of first-degree CHB (3 in the RRNL and 1 in the French cohort), along with 1 case of second-degree/normal sinus rhythm/first-degree CHB in the Italian cohort. Pedigrees were genotyped at HudsonAlpha Institute for Biotechnology (Huntsville, AL), and samples passing quality control (194 CHB offspring, 152 fathers, 167 mothers, and 91 unaffected siblings) were used in the analyses. There were 90 independent (unrelated) sibling pairs consisting of a child with CHB and an unaffected child, with the majority of these originating from the 139 complete trios (mother, father, and affected offspring); for 13 of the pedigrees with paternal genotype data, maternal genotype data were not available, and for 28 of the pedigrees with maternal genotype data, paternal genotype data were not available.
CHB was diagnosed if the following criteria were met: 1) the presence of a conduction defect (first-, second-, or thirddegree heart block) documented by electrocardiography, echocardiography, and/or history of pacemaker placement; and 2) the presence of antibodies to 52-kd SSA/Ro, 60-kd SSA/Ro, and/or 48-kd SSB/La in the child and/or mother, as determined by enzyme-linked immunosorbent assay using recombinant proteins or at a commercial laboratory (90% of cases were tested in the research laboratory of JPB and RMC).
For case-control analyses, 1,073 out-of-study healthy controls (635 female and 438 male) were obtained from the International Consortium on Systemic Lupus Erythematosus. All control subjects were of self-reported European ancestry.
Genotyping. All samples (from cases and controls) were genotyped on the Illumina Infinium Immunochip array, as part of the larger Systemic Lupus Erythematosus Immunochip Consortium (>25,000 cases and controls of 4 ethnicities) (6) . The Illumina iScan platform was used in accordance with protocols recommended by the manufacturer. Personnel at the Oklahoma Medical Research Foundation performed genotyping and completed genotype calling from intensity data, using OptiCall. SNPs that had call rates of <95%, differential missingness between cases and controls, significant departure from Hardy-Weinberg equilibrium, or a minor allele frequency of <0.01 were excluded from the analyses. Using the program Admixture, admixture estimates were computed on quality-controlled genotype data, and genetic outliers were removed from subsequent analyses. Familial relationships were verified by using identity-by-descent statistics with the software King (7), and genotype data that were inconsistent with Mendelian inheritance were removed.
Imputation for classic HLA alleles was performed using HLA Genotype Imputation with Attribute Bagging (HIBAG) (8) . Only high-quality SNPs were used as input, and the European Ancestry reference panel (provided by HIBAG) was utilized. For HLA class I alleles, HLA-C had the highest posterior probability (mean AE SD 0.97 AE 0.08). For each allele, C1 or C2 status was designated based on the amino acid at position 80, as originally identified by Winter and Long (5) (Lys80 = C2; Asn80 = C1). For each subject, C1 and C2 allele counts were based on best-guess imputed HLA alleles. Best-guess genotype data were completely consistent with Mendelian inheritance.
Imputation for KIR genes was completed using KIR*-IMP, version 1.1.1 (http://imp.mcri.edu.au) (9) . High-quality SNP genotypes were aligned with the reference sample and phased using ShapeIt. The resulting phased haplotype output files from ShapeIt were uploaded to the KIR*IMP imputation server. Four Mendelian inconsistencies for the KIR A/B haplotypes were observed and removed.
Statistical analysis. Findings in unrelated cases and in out-of-study controls were compared using a logistic regression model, which included admixture estimates as covariates. Admixture proportions were computed based on the Immunochip genotype data and with the program Admixture, as previously reported (4). McNemar's test was utilized to compare pairs of affected and unaffected siblings.
RESULTS
All pedigrees analyzed met the inclusion criteria of having an SSA/Ro-positive mother and available data on an affected CHB offspring. The RRNL cohort of children with CHB was 54% female, and 98% had advanced heart block (second-degree/third-degree CHB). Data from the Italian and French cohorts were similar, except that the proportion of female children was slightly higher in the European cohorts.
There was an enrichment of the C1 allele and a reduction of the C2 allele among mothers in the CHB pedigrees compared with female controls (odds ratio [OR] 0.63, P = 0.0014) ( Table 1 ). In contrast, the C2 allele was observed at an increased frequency in the fathers compared with male controls (OR 1.40, P = 0.0123). This sex-by-C2 interaction was statistically significant (P = 0.0002). Affected children did not exhibit enrichment for C1 or C2 alleles in comparison to outof-study controls (OR 1.14, P = 0.2627). However, when within-family data were analyzed, frequencies of C1 and C2 were found to be dissimilar in affected and unaffected offspring.
Pedigree analyses revealed differences in the HLA-C1 and C2 frequencies between affected and unaffected offspring. Specifically, the frequencies of C2 were comparable in the affected offspring and the fathers (0.42 among affected offspring; 0.45 among fathers), whereas among unaffected offspring, C2 frequencies were comparable to frequencies in the mothers (0.31 and 0.29, respectively). Differences in C2 frequency among affected and unaffected offspring within pedigrees were assessed by McNemar's test (n = 90 sibling pairs). This analysis showed a significant increase in the frequency of the C2 allele among affected offspring (OR 3.67, P = 0.0025) ( Table 2 ). The results were comparable in the subset of CHB-discordant sibling pairs whose mothers were homozygous for C1 (n = 46 pairs) (OR 2.75, P = 0.07). When the paired-sibling analysis was stratified by geographic region (US, Europe), the results were significant within each geographic stratum (OR 3.25, P = 0.0290 and OR 4.50, P = 0.0348 in the US and Europe, respectively). The replication and consistency of the effect sizes across the US and European cohorts suggest that the impact of the C1/C2 designation is representative of the CHB cohort and not an artifact of ancestral differences. The pedigree disequilibrium test (PDT), which incorporates both the differential parental transmission * Association analyses with out-of-study controls were performed using a logistic regression model with admixture estimates as covariates. In an additive genetic model for frequency of the C2 allele, the frequency was reduced among mothers in the congenital heart block (CHB) families versus female controls (odds ratio 0.63 [95% confidence interval 0.45-0.89], P = 0.0014) and increased among fathers in the CHB families versus male controls (odds ratio 1.40 [95% confidence interval 1.06-1.81], P = 0.0123). For sex interactions in parents relative to out-of-study controls, P = 0.0002. * Each pedigree is represented by a single sibling pair. McNemar's test showed a significant increase in the frequency of the C2 allele in the congenital heart block (CHB)-affected offspring (odds ratio 3.67, P = 0025) (P = 0.016 by pedigree disequilibrium test for the C2 allele based on Asn/Lys dimorphism at position 80).
to affected offspring and the discordance between siblings, also yielded significant results (P = 0.016). Given the interaction of C2 and KIRs, particularly within an AA (inhibitory) KIR haplotype, KIR genotypes were imputed using KIR*IMP. Frequencies of KIR AA haplotypes were not enriched among either affected children (AA 0.47) or unaffected children (AA 0.48) (P = 0.5485). Similarly, no differences between affected and unaffected siblings were identified for specific KIR alleles (Figure 1 ). Individual KIR frequencies were consistent with published frequencies in European populations (10) . PDT results were not significant for the AA haplotype.
DISCUSSION
In this study, the HLA-C-encoded supertypic epitope C2, which constitutes a high-affinity ligand for the inhibitory natural killer (NK) cell receptor KIR2DL1, was significantly enriched in patients with CHB compared with unaffected siblings. The HLA-C2 genotype comparisons of mothers and fathers with outof-study controls of the same sex revealed significant association within each sex but in opposite directions, yielding an intriguing sex-by-C2 interaction. The C1 and C2 frequencies in our control population are consistent with those reported in independent healthy cohorts of European ancestry (11) . In the assessment of the inhibitory KIR genotype, more broadly referred to as KIR AA, there were no differences between affected and unaffected children.
The contribution of KIRs to NK cell phenotype varies depending on canonical and noncanonical NK cell states. There is a strong dependence on the composition of KIRs, which are classically described in the context of major histocompatibility complex (MHC) class I recognition, whereby inhibitory KIRs engage self MHC ligands to suppress NK cell activation to confer a low risk of autoimmunity. In the setting of viral infection, activating KIR receptors recognize ligands expressed on infected cells, which results in cytokine production and cellular cytotoxicity by NK cells. The integration of signals from activating and inhibitory KIR receptors and their ligands ultimately determines NK cell functionality.
Inhibitory KIRs contribute to the noncanonical role of NK cells. Mechanistically, the inhibitory KIR2DL1 binds to C2 with higher affinity than the binding of KIR2DL2/3 to C1 and KIR2DL2 to C2. The exceptional specificity and affinity of the KIR2DL1-C2 interaction might lead to stronger inhibition of NK cells, which could compromise the ability of NK cells to limit macrophage activation. For example, it has been reported that NK cells play an important role in limiting or restraining macrophages (12) and dendritic cells (13) . Thus, the C2 epitope participates as a checkpoint inhibitor ligand, which would be anticipated to diminish a physiologic role of NK cells in forestalling the consequences of inflammation to host tissues. This might explain the presence of macrophages and giant cells consistently observed in autopsy tissue from the hearts of patients with CHB (14) , since C2 ligation conferred by the genetically vulnerable fetus would exhaust the restraining NK cells. These observations are compatible with a previously described model in which C2 ligands impair NK-mediated surveillance in childhood acute lymphoblastic leukemia (11) . In accordance with our HLA-C2 AS A RISK ALLELE FOR ANTI-SSA/Ro-ASSOCIATED CHBstudy, that model also does not include genetic differences in KIR. Further evidence to support this hypothesis was published by Meisgen et al, who performed an association study of targeted MHC molecules (HLA-A, Cw, and DRB1 alleles), using low-resolution typing of 87 CHB families (15) . HLA-Cw*05 variants (a C2 epitope) were significantly more frequently transmitted to affected offspring. However, there was no significance when accounting for parent of origin. Regarding another point raised in the report by Meisgen and colleagues, because HLA-Cw*06 was enriched in unaffected but not affected subjects, a hypothesis was advanced suggesting that HLA-Cw*05 serves as novel fetal HLA allele variant that confers CHB susceptibility, while Cw*06 emerges as a protective allele. Given that both alleles carry the C2 epitope, our current model and that of Meisgen et al are not in full alignment and require further investigation. Of note, both our study and the study by Meisgen and colleagues provide evidence of a paternal contribution to the development of CHB.
These data require careful consideration and recognition of their inferential limits. Similar to most studies of rare diseases, relatively small sample sizes limit power. However, this does not negate the positive associations observed, including replication across US and European cohorts. HLA class I and KIR assignments, which are based on imputation protocols, represent another limitation. However, the quality metrics of our assignments are within acceptable limits and practice.
In conclusion, there is an association of HLA-C Asn80Lys in children with CHB, which may represent a novel susceptibility allele. Given that the connection of autoantibodies and end-organ injury is complex, the inclusion of a defective checkpoint inhibitor in the model may provide new biologic insights.
